LONDON, Dec. 17, 2004 (PRIMEZONE) -- ASTRAZENECA -- Iressa update. Indepth interviews available now on www.cantos.com with Sir Tom McKillop, CEO, AstraZeneca (LSE:AZN); Dr Alan Barge, Medical Director for Iressa and Dr John Patterson, Executive Director for Development.
-- As AstraZeneca announces new data showing that its lung cancer drug Iressa has no survival benefit in the overall population, senior directors explain the findings and discuss the implications for both Iressa patients and the company itself.
This programming is available in video, audio and transcript.
It's free to view. All you need to do is register athttp://www.cantos.com
Cantos.com is an online financial website where top management of companies address the critical issues facing their businesses.
If you would like to contact us, please email enquiries@cantos.com.